BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pfizer readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Pfizer's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06641466-10363@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20261129
DTEND;VALUE=DATE:20261130
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT06641466)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Women When Used for 
 Intermittent Prevention of Menstrual Migraine\nEstimated primary completio
 n: 29 November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rimegepant-nurtec-odt#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06641466
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06221748-2454@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase 2/3 readout est. (NCT06221748)
DESCRIPTION:Disitamab Vedotin\, phase 2/3\, Gastric Cancer.\nStudy: DV Comb
 ined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and 
 Gastroesophageal Junction Adenocarcinoma After Progression on First-line T
 herapy\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06221748
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029711-5938@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20261202
DTEND;VALUE=DATE:20261203
SUMMARY:PF-06651600: Phase 3 readout est. (NCT07029711)
DESCRIPTION:PF-06651600\, phase 3.\nStudy: A Study to Learn About Medicine 
 Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alo
 pecia Areata\nEstimated primary completion: 2 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07029711
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07500506-11283@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20261204
DTEND;VALUE=DATE:20261205
SUMMARY:PF-07307405: Phase 3 readout est. (NCT07500506)
DESCRIPTION:PF-07307405\, phase 3\, Lyme Disease.\nStudy: A Study to Learn 
 About the Safety\, Tolerability\, and Immunogenicity of a Fifth Dose of 6-
 Valent OspA-Based Lyme Disease Vaccine\nEstimated primary completion: 4 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-07307
 405#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07500506
URL:https://assetmemo.bio/drug/pf-07307405#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228390-5938@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261209
SUMMARY:PF-06651600: Phase 2 readout est. (NCT07228390)
DESCRIPTION:PF-06651600\, phase 2.\nStudy: A 16-Week Study to Learn About t
 he Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful 
 Red Skin Lumps\, Known by the Medical Term\, Hidradenitis Suppurativa\, or
  HS.\nEstimated primary completion: 8 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07228390
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04879329-2454@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT04879329)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Urothelial Carcinoma.\nStudy: A S
 tudy of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer
  That Expresses HER2\nEstimated primary completion: 11 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04879329
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219615-5938@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:PF-06651600: Phase 2 readout est. (NCT07219615)
DESCRIPTION:PF-06651600\, phase 2.\nStudy: A Study to Learn About Ritleciti
 nib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults
 .\nEstimated primary completion: 25 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07219615
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909397-9034@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT05909397)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letroz
 ole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer\nEstimated prima
 ry completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05909397
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910528-20@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:afimkibart: Phase 2 readout est. (NCT05910528)
DESCRIPTION:afimkibart\, phase 2\, Crohn's Disease.\nStudy: Afimkibart (RO7
 790121) for the Treatment of Moderate to Severe Active Crohn's Disease\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05910528
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04553133-9034@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04553133)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: PF-07104091 as a Single Agent and in Combination Therapy\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04553133
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-1970@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lorlatinib: Phase 3 readout est. (NCT05059522)
DESCRIPTION:Lorlatinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cont
 inued Access Study for Participants Deriving Benefit in Pfizer-Sponsored A
 velumab Parent Studies That Are Closing\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lorlat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05059522
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05302284-2454@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05302284)
DESCRIPTION:Disitamab Vedotin\, phase 3\, Urothelial Carcinoma.\nStudy: A S
 tudy of RC48-ADC Combined With Toripalimab For First-line Treatment of Uro
 thelial Carcinoma\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05302284
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05911295-2454@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT05911295)
DESCRIPTION:Disitamab Vedotin\, phase 3\, Urothelial Carcinoma.\nStudy: Dis
 itamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated 
 Urothelial Cancer Expressing HER2\nEstimated primary completion: 29 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/disitamab-ved
 otin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05911295
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589986-20@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:afimkibart: Phase 3 readout est. (NCT06589986)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to A
 ssess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for 
 Induction and Maintenance Therapy in Participants With Moderately to Sever
 ely Active Ulcerative Colitis\nEstimated primary completion: 30 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/afimkibart#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06589986
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05262400-9131@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Atirmociclib: Phase 1/2 readout est. (NCT05262400)
DESCRIPTION:Atirmociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study to Learn About the Study Medicine (Called PF-07220060 in C
 ombination With PF-07104091) In Participants With Breast Cancer and Solid 
 Tumors\nEstimated primary completion: 26 February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/atirmociclib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05262400
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073417-193@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270227
DTEND;VALUE=DATE:20270228
SUMMARY:ecnoglutide: Phase 2 readout est. (NCT07073417)
DESCRIPTION:ecnoglutide\, phase 2\, Obesity.\nStudy: A Study to Compare XW0
 03 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLI
 MMER-UP-SWITCH)\nEstimated primary completion: 27 February 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ecnoglutide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07073417
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06551324-7732@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Mevrometostat: Phase 3 readout est. (NCT06551324)
DESCRIPTION:Mevrometostat\, phase 3.\nStudy: A Study to Learn About the Inv
 estigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC
  Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer 
 (MEVPRO-1).\nEstimated primary completion: 28 February 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/mevrometostat#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06551324
URL:https://assetmemo.bio/drug/mevrometostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06977581-1455@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:tilrekimig: Phase 2 readout est. (NCT06977581)
DESCRIPTION:tilrekimig\, phase 2\, Asthma.\nStudy: A Study to Learn About t
 he Study Medicine Called PF-07275315 in People With Moderate-To-Severe Ast
 hma\nEstimated primary completion: 8 March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06977581
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04624230-15@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270317
DTEND;VALUE=DATE:20270318
SUMMARY:Xeljanz (tofacitinib): Phase 3 readout est. (NCT04624230)
DESCRIPTION:Xeljanz (tofacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: E
 valuation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering
  From Moderate to Severe Ulcerative Colitis\nEstimated primary completion:
  17 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tofac
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04624230
URL:https://assetmemo.bio/drug/tofacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05548127-9103@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270324
DTEND;VALUE=DATE:20270325
SUMMARY:Veppanu (Vepdegestrant): Phase 1/2 readout est. (NCT05548127)
DESCRIPTION:Veppanu (Vepdegestrant)\, phase 1/2\, HR+/HER2- Metastatic Brea
 st Cancer.\nStudy: TACTIVE-U: A Study to Learn About the Study Medicine (V
 epdegestrant) When Given With Other Medicines in People With Advanced or M
 etastatic Breast Cancer (Sub-Study A)\nEstimated primary completion: 24 Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vepdegestra
 nt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5548127
URL:https://assetmemo.bio/drug/vepdegestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270044-1996@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Binimetinib: Phase 3 readout est. (NCT05270044)
DESCRIPTION:Binimetinib\, phase 3\, Melanoma.\nStudy: Adjuvant Encorafenib 
 and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.\nEsti
 mated primary completion: 31 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05270044
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06163326-5938@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:PF-06651600: Phase 3 readout est. (NCT06163326)
DESCRIPTION:PF-06651600\, phase 3\, Vitiligo.\nStudy: A 52-Week Study to Le
 arn About the Safety and Effects of Ritlecitinib in Participants With Nons
 egmental Vitiligo\nEstimated primary completion: 31 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06163326
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07137598-20@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270417
DTEND;VALUE=DATE:20270418
SUMMARY:afimkibart: Phase 2 readout est. (NCT07137598)
DESCRIPTION:afimkibart\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study to
  Assess the Efficacy and Safety of RO7790121 in Participants With Moderate
  to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot To
 lerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)\nE
 stimated primary completion: 17 April 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07137598
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05179226-591@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 3 readout est. (
 NCT05179226)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 3\, Iron De
 ficiency Anemia.\nStudy: Multi-center Trial of Ferric Derisomaltose in Chi
 ldren 0 to <18 Years of Age With Iron Deficiency Anemia\nEstimated primary
  completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ferric-derisomaltose#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05179226
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807268-1302@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270502
DTEND;VALUE=DATE:20270503
SUMMARY:Cibinqo (abrocitinib): Phase 3 readout est. (NCT06807268)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 3.\nStudy: A Study of the Medicin
 e Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moder
 ate-to-Severe Eczema\nEstimated primary completion: 2 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/abrocitinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06807268
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06155396-2454@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06155396)
DESCRIPTION:Disitamab Vedotin\, phase 2.\nStudy: A Study of RC48-ADC Combin
 ation With Zimberelimab Injection Therapies at Least First-line Platinum-c
 ontaining Standard Therapy Failed With Recurrent or Metastatic Cervical Ca
 ncer\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06155396
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-9038@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Exemestane: Phase 3 readout est. (NCT07062965)
DESCRIPTION:Exemestane\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Learn About the Study Medicine Called PF-07248144 in Combin
 ation With Fulvestrant in People With HR-positive\, HER2-negative Advanced
  or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatmen
 t.\nEstimated primary completion: 22 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/exemestane#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07062965
URL:https://assetmemo.bio/drug/exemestane#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072183-5938@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:PF-06651600: Phase 3 readout est. (NCT06072183)
DESCRIPTION:PF-06651600\, phase 3\, Vitiligo.\nStudy: A 104-Week Study of R
 itlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and
  Stable) Tranquillo 2\nEstimated primary completion: 30 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06072183
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747506-11026@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 2 readout
  est. (NCT07747506)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 2\, 
 Ovarian Cancer.\nStudy: Continued Access to Avutometinib in Combination Wi
 th Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (
 LGSOC)\nEstimated primary completion: 1 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-c
 o-pack#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07747506
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575932-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270804
DTEND;VALUE=DATE:20270805
SUMMARY:Berobenatide: Phase 2 readout est. (NCT07575932)
DESCRIPTION:Berobenatide\, phase 2\, Obesity.\nStudy: A Study of PF-0865394
 5 and PF-08653944 in Adults With Overweight or Obesity\nEstimated primary 
 completion: 4 August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/berobenatide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07575932
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317416-3143@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270804
DTEND;VALUE=DATE:20270805
SUMMARY:Elranatamab: Phase 3 readout est. (NCT05317416)
DESCRIPTION:Elranatamab\, phase 3\, Multiple Myeloma.\nStudy: Study With El
 ranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple My
 eloma After Transplant\nEstimated primary completion: 4 August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05317416
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07929298-193@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270903
DTEND;VALUE=DATE:20270904
SUMMARY:ecnoglutide: Phase 2 readout est. (NCT07929298)
DESCRIPTION:ecnoglutide\, phase 2\, Obesity.\nStudy: A Study to Evaluate th
 e Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With 
 Overweight or Obesity\nEstimated primary completion: 3 September 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ecnoglutide#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07929298
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311850-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270921
DTEND;VALUE=DATE:20270922
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07311850)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety o
 f MET097 Once-Weekly in People With Overweight or Obesity\nEstimated prima
 ry completion: 21 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/berobenatide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07311850
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013474-11275@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Ibuzatrelvir: Phase 3 readout est. (NCT07013474)
DESCRIPTION:Ibuzatrelvir\, phase 3\, COVID-19.\nStudy: A Study to Learn Abo
 ut the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severel
 y Immunocompromised\nEstimated primary completion: 28 September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ibuzatrelvir#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07013474
URL:https://assetmemo.bio/drug/ibuzatrelvir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06629779-7732@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Mevrometostat: Phase 3 readout est. (NCT06629779)
DESCRIPTION:Mevrometostat\, phase 3\, Metastatic Castration-Resistant Prost
 ate Cancer.\nStudy: A Study to Learn How PF-06821497 (Mevrometostat) Works
  in Men With Metastatic Castration-resistant Prostate Cancer.\nEstimated p
 rimary completion: 30 September 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/mevrometostat#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06629779
URL:https://assetmemo.bio/drug/mevrometostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679140-11275@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Ibuzatrelvir: Phase 3 readout est. (NCT06679140)
DESCRIPTION:Ibuzatrelvir\, phase 3\, COVID-19.\nStudy: A Study to Learn Abo
 ut a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients W
 ith COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease\n
 Estimated primary completion: 1 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ibuzatrelvir#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06679140
URL:https://assetmemo.bio/drug/ibuzatrelvir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400653-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07400653)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine (PF-08653944) in People With Obesity or Overweight an
 d Type 2 Diabetes (T2D)\nEstimated primary completion: 12 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07400653
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227012-1989@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:PF-08634404: Phase 1/2 readout est. (NCT07227012)
DESCRIPTION:PF-08634404\, phase 1/2.\nStudy: Symbiotic-GI-13: A Study to Le
 arn About Study Medicine Called PF-08634404 as a Single Treatment and Comb
 ination Treatment in Adult Participants With a Liver Cancer Called Hepatoc
 ellular Carcinoma\, That is Too Advanced to be Removed by Surgery and May 
 Have Spread to Other Parts of the Body.\nEstimated primary completion: 18 
 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-0863
 4404#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07227012
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966453-2454@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20271025
DTEND;VALUE=DATE:20271026
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT06966453)
DESCRIPTION:Disitamab Vedotin\, phase 1/2\, HR+/HER2- Metastatic Breast Can
 cer.\nStudy: A Study of Disitamab Vedotin in Adults With HER2 Expressing A
 dvanced Breast Cancer\nEstimated primary completion: 25 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06966453
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227415-1989@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20271102
DTEND;VALUE=DATE:20271103
SUMMARY:PF-08634404: Phase 1/2 readout est. (NCT07227415)
DESCRIPTION:PF-08634404\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Symbiot
 ic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alo
 ne and in Combination With Other Anticancer Therapies in Adults With Local
 ly Advanced or Metastatic Renal Cell Cancer\nEstimated primary completion:
  2 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-
 08634404#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07227415
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07475806-2121@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Enfortumab Vedotin: Phase 2 readout est. (NCT07475806)
DESCRIPTION:Enfortumab Vedotin\, phase 2\, Bladder Cancer.\nStudy: A Study 
 to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People Wi
 th Muscle-invasive Bladder Cancer Keep Their Bladder\nEstimated primary co
 mpletion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/enfortumab-vedotin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07475806
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05745740-2454@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT05745740)
DESCRIPTION:Disitamab Vedotin\, phase 1/2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Ad
 vanced or Metastasis NSCLC With HER2 Mutation\nEstimated primary completio
 n: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 isitamab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05745740
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929806-591@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Monoferric / Monofer (Ferric derisomaltose): Phase 3 readout est. (
 NCT06929806)
DESCRIPTION:Monoferric / Monofer (Ferric derisomaltose)\, phase 3\, Heart F
 ailure.\nStudy: Multi-center Trial of Ferric Derisomaltose Versus no Intra
 venous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Fail
 ure\nEstimated primary completion: 1 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06929806
URL:https://assetmemo.bio/drug/ferric-derisomaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387094-193@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20271216
DTEND;VALUE=DATE:20271217
SUMMARY:ecnoglutide: Phase 3 readout est. (NCT07387094)
DESCRIPTION:ecnoglutide\, phase 3\, Obesity.\nStudy: A Study of XW003 in Ob
 ese Participants With Obstructive Sleep Apnea But Not Receive Positive Air
 way Pressure Therapy\nEstimated primary completion: 16 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ecnoglutide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07387094
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421700-1989@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:PF-08634404: Phase 1/2 readout est. (NCT07421700)
DESCRIPTION:PF-08634404\, phase 1/2.\nStudy: Symbiotic-GU-06: A Study to Le
 arn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in U
 rothelial Cancer\nEstimated primary completion: 28 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pf-08634404#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07421700
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05253651-2271@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tucatinib: Phase 3 readout est. (NCT05253651)
DESCRIPTION:Tucatinib\, phase 3\, Colorectal Cancer.\nStudy: A Study of Tuc
 atinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in 
 First-line HER2+ Metastatic Colorectal Cancer\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tucatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05253651
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04400695-2454@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT04400695)
DESCRIPTION:Disitamab Vedotin\, phase 3\, HR+/HER2- Metastatic Breast Cance
 r.\nStudy: A Study of RC48-ADC for the Treatment of Locally Advanced or Me
 tastatic Breast Cancer With Low Expression of HER2\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04400695
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989437-642@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280123
DTEND;VALUE=DATE:20280124
SUMMARY:Ponsegromab: Phase 2/3 readout est. (NCT06989437)
DESCRIPTION:Ponsegromab\, phase 2/3.\nStudy: A Study to Learn About the Med
 icine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread a
 nd Caused Significant Body Weight Loss and Fatigue\nEstimated primary comp
 letion: 23 January 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ponsegromab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06989437
URL:https://assetmemo.bio/drug/ponsegromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226882-11283@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280127
DTEND;VALUE=DATE:20280128
SUMMARY:PF-07307405: Phase 3 readout est. (NCT07226882)
DESCRIPTION:PF-07307405\, phase 3\, Lyme Disease.\nStudy: A Study to Learn 
 About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adul
 ts\nEstimated primary completion: 27 January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pf-07307405#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07226882
URL:https://assetmemo.bio/drug/pf-07307405#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07145918-705@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Emraclidine: Phase 2 readout est. (NCT07145918)
DESCRIPTION:Emraclidine\, phase 2\, Schizophrenia.\nStudy: A Study to Asses
 s Adverse Events\, Change in Disease Activity\, and How Oral Emraclidine M
 oves Through the Body in Adult Participants With Schizophrenia\nEstimated 
 primary completion: February 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/emraclidine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07145918
URL:https://assetmemo.bio/drug/emraclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216027-1457@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:PF-08049820: Phase 2 readout est. (NCT07216027)
DESCRIPTION:PF-08049820\, phase 2\, Atopic Dermatitis.\nStudy: A Study to L
 earn About Study Medicine Called PF-08049820 in People With Eczema\nEstima
 ted primary completion: 2 February 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pf-08049820#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07216027
URL:https://assetmemo.bio/drug/pf-08049820#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845500-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07845500)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) 
 to Help Keep Weight Off in People With Overweight or Obesity\nEstimated pr
 imary completion: 16 February 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/berobenatide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07845500
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398417-10867@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Esreboxetine: Phase 3 readout est. (NCT07398417)
DESCRIPTION:Esreboxetine\, phase 3\, Fibromyalgia.\nStudy: Fibromyalgia Res
 ponse With Esreboxetine Evaluated Using a Randomized Withdrawal Research D
 esign\nEstimated primary completion: March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/esreboxetine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07398417
URL:https://assetmemo.bio/drug/esreboxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765888-1455@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280310
DTEND;VALUE=DATE:20280311
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07765888)
DESCRIPTION:tilrekimig\, phase 3\, Atopic Dermatitis.\nStudy: A Study to Le
 arn About the Study Medicine Called Tilrekimig in People With Moderate-to-
 Severe Eczema\nEstimated primary completion: 10 March 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07765888
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07144280-2168@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280310
DTEND;VALUE=DATE:20280311
SUMMARY:Fetrastobart vedotin: Phase 3 readout est. (NCT07144280)
DESCRIPTION:Fetrastobart vedotin\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL
 1V Versus Docetaxel in Adult Participants With Previously-Treated Programm
 ed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
 \nEstimated primary completion: 10 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07144280
URL:https://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07792954-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280314
DTEND;VALUE=DATE:20280315
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07792954)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Plac
 ebo in Chinese Adults With Overweight or Obesity\nEstimated primary comple
 tion: 14 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 berobenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07792954
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06873945-5938@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280319
DTEND;VALUE=DATE:20280320
SUMMARY:PF-06651600: Phase 3 readout est. (NCT06873945)
DESCRIPTION:PF-06651600\, phase 3.\nStudy: A Study of 2 Doses of Ritlecitin
 ib in People 12 Years of Age and Older With Alopecia Areata\nEstimated pri
 mary completion: 19 March 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pf-06651600#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06873945
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07476287-1989@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280324
DTEND;VALUE=DATE:20280325
SUMMARY:PF-08634404: Phase 2 readout est. (NCT07476287)
DESCRIPTION:PF-08634404\, phase 2.\nStudy: Symbiotic-Lung-14: A Study to Le
 arn About the Study Medicine Called PF08634404 in Combination With Chemoth
 erapy in Adult Participants With Transformed Small Cell Lung Cancer\nEstim
 ated primary completion: 24 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pf-08634404#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07476287
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733765-5938@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:PF-06651600: Phase 3 readout est. (NCT07733765)
DESCRIPTION:PF-06651600\, phase 3.\nStudy: A Study in Young People and Adul
 ts to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair L
 oss\, Known by the Medical Term as Moderate Alopecia Areata\nEstimated pri
 mary completion: 26 April 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pf-06651600#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07733765
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823608-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07823608)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Monthly Dosing Study Medicine Called Berobenatide in Adults With Bre
 athing Problems During Sleep and Overweight or Obesity Who Use a Breathing
  Machine (PAP) (VESPER-OSA 1)\nEstimated primary completion: 30 April 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07823608
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637162-10867@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Esreboxetine: Phase 3 readout est. (NCT07637162)
DESCRIPTION:Esreboxetine\, phase 3\, Fibromyalgia.\nStudy: Open-Label Safet
 y Study of AXS-14 in Subjects With Fibromyalgia\nEstimated primary complet
 ion: May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/esrebo
 xetine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07637162
URL:https://assetmemo.bio/drug/esreboxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595549-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280504
DTEND;VALUE=DATE:20280505
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07595549)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine Called Berobenatide (PF-08653944) in People With Over
 weight or Obesity\nEstimated primary completion: 4 May 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/berobenatide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07595549
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06991257-628@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280508
DTEND;VALUE=DATE:20280509
SUMMARY:PF-07328948: Phase 2 readout est. (NCT06991257)
DESCRIPTION:PF-07328948\, phase 2\, Heart Failure.\nStudy: A Study to Learn
  About the Study Medicine Called PF-07328948 in Adults With Heart Failure 
 (BRANCH-HF)\nEstimated primary completion: 8 May 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pf-07328948#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06991257
URL:https://assetmemo.bio/drug/pf-07328948#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944496-2454@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT06944496)
DESCRIPTION:Disitamab Vedotin\, phase 3.\nStudy: A Study of Disitamab Vedot
 in Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combine
 d With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junct
 ion Adenocarcinoma\nEstimated primary completion: 15 May 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06944496
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846683-20@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:afimkibart: Phase 3 readout est. (NCT07846683)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to A
 ssess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimk
 ibart in Participants With Moderately to Severely Active Ulcerative Coliti
 s\nEstimated primary completion: 31 May 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07846683
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734311-193@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:ecnoglutide: Phase 3 readout est. (NCT07734311)
DESCRIPTION:ecnoglutide\, phase 3\, Obesity.\nStudy: A Study of Econoglutid
 e Injection in Obese Participants With Knee Osteoarthritis (KOA)\nEstimate
 d primary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ecnoglutide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07734311
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881757-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07881757)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Monthly Dosing Study Medicine Called Berobenatide in Adults With Bre
 athing Problems During Sleep and Overweight or Obesity Who Do Not Use a Br
 eathing Machine (PAP) (VESPER-OSA 2)\nEstimated primary completion: 1 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07881
 757
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874633-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07874633)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Pla
 cebo in Chinese Adults With Overweight or Obesity\nEstimated primary compl
 etion: 6 June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 erobenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07874633
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836270-193@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280608
DTEND;VALUE=DATE:20280609
SUMMARY:ecnoglutide: Phase 3 readout est. (NCT07836270)
DESCRIPTION:ecnoglutide\, phase 3\, Obesity.\nStudy: A Study of Ecnoglutide
  Injection in Overweight or Obese Chinese Adolescents\nEstimated primary c
 ompletion: 8 June 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ecnoglutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07836270
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07434050-193@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280619
DTEND;VALUE=DATE:20280620
SUMMARY:ecnoglutide: Phase 3 readout est. (NCT07434050)
DESCRIPTION:ecnoglutide\, phase 3\, Obesity.\nStudy: A Study of XW003 in Ob
 ese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pr
 essure Therapy\nEstimated primary completion: 19 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ecnoglutide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07434050
URL:https://assetmemo.bio/drug/ecnoglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489066-1989@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280729
DTEND;VALUE=DATE:20280730
SUMMARY:PF-08634404: Phase 2 readout est. (NCT07489066)
DESCRIPTION:PF-08634404\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sym
 biotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination
  in Early-stage or Locally Advanced NSCLC\nEstimated primary completion: 2
 9 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-08634
 404#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07489066
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915609-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280821
DTEND;VALUE=DATE:20280822
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07915609)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Ov
 erweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)\nEstimat
 ed primary completion: 21 August 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/berobenatide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07915609
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919678-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280822
DTEND;VALUE=DATE:20280823
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07919678)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Study Medicine Called Berobenatide in Adults With Knee Pain and Overweig
 ht or Obesity (VESPER-OA 1)\nEstimated primary completion: 22 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07919678
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979076-466@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:MS-553: Phase 1/2 readout est. (NCT06979076)
DESCRIPTION:MS-553\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: A Ph
 ase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Ref
 ractory or Relapsed CLL/SLL\nEstimated primary completion: September 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ms-553#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06979076
URL:https://assetmemo.bio/drug/ms-553#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783425-1455@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280908
DTEND;VALUE=DATE:20280909
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07783425)
DESCRIPTION:tilrekimig\, phase 3\, Atopic Dermatitis.\nStudy: A Study to Le
 arn About the Study Medicine Called Tilrekimig in People With Moderate-to 
 Severe Eczema\nEstimated primary completion: 8 September 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07783425
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07028853-7732@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280912
DTEND;VALUE=DATE:20280913
SUMMARY:Mevrometostat: Phase 3 readout est. (NCT07028853)
DESCRIPTION:Mevrometostat\, phase 3.\nStudy: This Study Will Explore Whethe
 r a Combination of the Investigational Drug Mevrometostat (PF-06821497) an
 d Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Particip
 ants With mCSPC Who Are ARPI naïve.\nEstimated primary completion: 12 Sep
 tember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mevromet
 ostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07028853
URL:https://assetmemo.bio/drug/mevrometostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07932925-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07932925)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Safety and Effectiveness of Berobenatide in Women With Urine Leakage
  and With Obesity or Overweight (VESPER-SUI)\nEstimated primary completion
 : 13 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/be
 robenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07932925
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072781-11026@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 3 readout
  est. (NCT06072781)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 3\, 
 Ovarian Cancer.\nStudy: A Study of Avutometinib (VS-6766) + Defactinib (VS
 -6063) in Recurrent Low-Grade Serous Ovarian Cancer\nEstimated primary com
 pletion: 15 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/avutometinib-defactinib-avmapki-fakzynja-co-pack#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06072781
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729462-10363@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20281021
DTEND;VALUE=DATE:20281022
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT07729462)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Adults When Used for
  the Prevention of Chronic Migraine\nEstimated primary completion: 21 Octo
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rimegepant-
 nurtec-odt#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07729462
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-11026@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack): Phase 1/2 reado
 ut est. (NCT07020221)
DESCRIPTION:Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)\, phase 1/2.
 \nStudy: A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated S
 olid Tumors\nEstimated primary completion: December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzy
 nja-co-pack#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07020221
URL:https://assetmemo.bio/drug/avutometinib-defactinib-avmapki-fakzynja-co-
 pack#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819878-20@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:afimkibart: Phase 3 readout est. (NCT06819878)
DESCRIPTION:afimkibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Asse
 ss the Efficacy and Safety of Induction and Maintenance Therapy With Afimk
 ibart (RO7790121) in Participants With Moderately to Severely Active Crohn
 's Disease\nEstimated primary completion: 31 December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06819878
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819891-20@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:afimkibart: Phase 3 readout est. (NCT06819891)
DESCRIPTION:afimkibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Asse
 ss the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121
 ) in Participants With Moderately to Severely Active Crohn's Disease\nEsti
 mated primary completion: 31 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06819891
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760637-9131@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Atirmociclib: Phase 3 readout est. (NCT06760637)
DESCRIPTION:Atirmociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-
 negative Breast Cancer Who Have Not Received Anticancer Treatment for Adva
 nced/Metastatic Disease\nEstimated primary completion: 2 January 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/atirmociclib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06760637
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04649242-10363@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290109
DTEND;VALUE=DATE:20290110
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT04649242)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: Randomize
 d Study in Children and Adolescents With Migraine: Acute Treatment\nEstima
 ted primary completion: 9 January 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04649242
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794774-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290221
DTEND;VALUE=DATE:20290222
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07794774)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Safety and Effects of Once-monthly Treatment With Berobenatide in Adults
  With Obesity Disease in Japan (VESPER-JM)\nEstimated primary completion: 
 21 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ber
 obenatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07794774
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222566-1989@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290227
DTEND;VALUE=DATE:20290228
SUMMARY:PF-08634404: Phase 3 readout est. (NCT07222566)
DESCRIPTION:PF-08634404\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Sym
 biotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634
 404 in Combination With Chemotherapy in Adult Participants With Locally Ad
 vanced or Metastatic Non-Small Cell Lung Cancer\nEstimated primary complet
 ion: 27 February 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pf-08634404#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07222566
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227298-1989@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290308
DTEND;VALUE=DATE:20290309
SUMMARY:PF-08634404: Phase 1/2 readout est. (NCT07227298)
DESCRIPTION:PF-08634404\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 ymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-0863
 4404 in Combination With Different Anticancer Agents in Advanced Cancers\n
 Estimated primary completion: 8 March 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pf-08634404#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07227298
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794761-179@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290314
DTEND;VALUE=DATE:20290315
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07794761)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Safety and Effects of Once-weekly Treatment With Berobenatide in Adults 
 With Obesity Disease in Japan (VESPER-JW)\nEstimated primary completion: 1
 4 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beroben
 atide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07794761
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06378242-2454@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT06378242)
DESCRIPTION:Disitamab Vedotin\, phase 1/2.\nStudy: To Evaluate the Safety\,
  Efficacy\, and Pharmacokinetics of Intravesical Instiliations of Disitama
 b Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer 
 (NMIBC) That Express HER2\nEstimated primary completion: 15 March 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/disitamab-vedotin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06378242
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05156398-10363@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT05156398)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: Efficacy 
 and Safety Study of Rimegepant for the Preventative Treatment of Migraine 
 in Pediatric Subjects\nEstimated primary completion: 27 March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05156398
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823595-1302@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290410
DTEND;VALUE=DATE:20290411
SUMMARY:Cibinqo (abrocitinib): Phase 3 readout est. (NCT07823595)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 3\, Atopic Dermatitis.\nStudy: Ab
 rocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Year
 s of Age\nEstimated primary completion: 10 April 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/abrocitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07823595
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772921-1455@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07772921)
DESCRIPTION:tilrekimig\, phase 3\, Asthma.\nStudy: A Study to Learn About t
 he Study Medicine Called Tilrekimig in People With Severe Asthma\nEstimate
 d primary completion: 1 June 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tilrekimig#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07772921
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578649-1989@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:PF-08634404: Phase 3 readout est. (NCT07578649)
DESCRIPTION:PF-08634404\, phase 3\, Endometrial Cancer.\nStudy: Symbiotic-G
 YN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Com
 bination With Chemotherapy in Adult Participants With Advanced or Recurren
 t MMR-proficient Endometrial Cancer\nEstimated primary completion: 1 June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-08634404#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0757864
 9
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07869043-1455@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290607
DTEND;VALUE=DATE:20290608
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07869043)
DESCRIPTION:tilrekimig\, phase 3\, Asthma.\nStudy: A Study to Learn About t
 he Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe A
 sthma\nEstimated primary completion: 7 June 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07869043
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05287126-13@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290616
DTEND;VALUE=DATE:20290617
SUMMARY:Velsipity (etrasimod): Phase 2 readout est. (NCT05287126)
DESCRIPTION:Velsipity (etrasimod)\, phase 2\, Ulcerative Colitis.\nStudy: A
  Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Coli
 tis\nEstimated primary completion: 16 June 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/etrasimod#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05287126
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03950232-13@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290619
DTEND;VALUE=DATE:20290620
SUMMARY:Velsipity (etrasimod): Phase 3 readout est. (NCT03950232)
DESCRIPTION:Velsipity (etrasimod)\, phase 3\, Ulcerative Colitis.\nStudy: A
 n Extension Study for Treatment of Moderately to Severely Active Ulcerativ
 e Colitis\nEstimated primary completion: 19 June 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/etrasimod#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03950232
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287995-2121@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT07287995)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2.\nStudy: A Study of ASP2998 Give
 n by Itself and Given With Standard Therapies in People With Solid Tumors\
 nEstimated primary completion: 30 June 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07287995
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315750-2454@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Disitamab Vedotin: Phase 3 readout est. (NCT07315750)
DESCRIPTION:Disitamab Vedotin\, phase 3.\nStudy: A Study of Disitamab Vedot
 in Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined
  With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Ad
 vanced Gastric or Gastroesophageal Junction Adenocarcinoma.\nEstimated pri
 mary completion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/disitamab-vedotin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07315750
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06157892-2271@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290728
DTEND;VALUE=DATE:20290729
SUMMARY:Tucatinib: Phase 2 readout est. (NCT06157892)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: A Study of Disitam
 ab Vedotin With Other Anticancer Drugs in Solid Tumors\nEstimated primary 
 completion: 28 July 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tucatinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06157892
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9034@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04606446)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of PF-07248144 in Advanced or Metastatic Solid Tumors
 \nEstimated primary completion: 27 August 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557449-9131@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20291007
DTEND;VALUE=DATE:20291008
SUMMARY:Atirmociclib: Phase 2 readout est. (NCT04557449)
DESCRIPTION:Atirmociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study to Test the Safety and Tolerability of PF-07220060 in Particip
 ants With Advance Solid Tumors\nEstimated primary completion: 7 October 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/atirmociclib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04557449
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00610051-618@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:alprostadil: Phase 3 readout est. (NCT00610051)
DESCRIPTION:alprostadil\, phase 3\, Heart Failure.\nStudy: ALP-1 Continuous
  Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Fai
 lure\nEstimated primary completion: November 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/alprostadil#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT00610051
URL:https://assetmemo.bio/drug/alprostadil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05700448-2747@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Cejemly (Sugemalimab): Phase 3 readout est. (NCT05700448)
DESCRIPTION:Cejemly (Sugemalimab)\, phase 3.\nStudy: Study of Sugemalimab (
 or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell 
 Lymphoma\nEstimated primary completion: December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sugemalimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05700448
URL:https://assetmemo.bio/drug/sugemalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05226871-9034@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT05226871)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study for Participants Continuing From Pfizer-sponsored Pal
 bociclib (a Study Medicine) Studies\nEstimated primary completion: 31 Dece
 mber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbocicli
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 226871
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222800-1989@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20300223
DTEND;VALUE=DATE:20300224
SUMMARY:PF-08634404: Phase 3 readout est. (NCT07222800)
DESCRIPTION:PF-08634404\, phase 3\, Colorectal Cancer.\nStudy: Symbiotic-GI
 -03: A Study to Learn About the Study Medicine Called PF-08634404 in Combi
 nation With Chemotherapy in Adult Participants With Metastatic Colorectal 
 Cancer\nEstimated primary completion: 23 February 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pf-08634404#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07222800
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616194-10363@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20300226
DTEND;VALUE=DATE:20300227
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT06616194)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: A Study t
 o Learn About the Study Medicine Called Rimegepant in Adolescents With Fre
 quent Migraine\nEstimated primary completion: 26 February 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06616194
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158242-20@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:afimkibart: Phase 3 readout est. (NCT07158242)
DESCRIPTION:afimkibart\, phase 3\, Ulcerative Colitis.\nStudy: A Study to E
 valuate the Pharmacokinetics\, Safety and Efficacy of Afimkibart (RO779012
 1) in Children With Moderately to Severely Active Ulcerative Colitis\nEsti
 mated primary completion: 31 March 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/afimkibart#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07158242
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566156-2121@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Enfortumab Vedotin: Phase 3 readout est. (NCT07566156)
DESCRIPTION:Enfortumab Vedotin\, phase 3\, Bladder Cancer.\nStudy: Enfortum
 ab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiother
 apy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)\nEstimat
 ed primary completion: 31 March 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/enfortumab-vedotin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07566156
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298421-20@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:afimkibart: Phase 3 readout est. (NCT07298421)
DESCRIPTION:afimkibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Asse
 ss the Pharmacokinetics\, Effectiveness and Safety of Afimkibart for Induc
 tion and Maintenance Therapy in Children With Moderately to Severely Activ
 e Crohn's Disease\nEstimated primary completion: 31 May 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07298421
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226999-1989@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20300614
DTEND;VALUE=DATE:20300615
SUMMARY:PF-08634404: Phase 2/3 readout est. (NCT07226999)
DESCRIPTION:PF-08634404\, phase 2/3.\nStudy: Symbiotic-Lung-04: A Study to 
 Learn About the Study Medicine Called PF-08634404 in Combination With Chem
 otherapy and With Tarlatamab\, Alone or With Chemotherapy\, in Adult Parti
 cipants With Extensive-Stage Small Cell Lung Cancer\nEstimated primary com
 pletion: 14 June 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pf-08634404#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07226999
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029828-5938@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20300626
DTEND;VALUE=DATE:20300627
SUMMARY:PF-06651600: Phase 3 readout est. (NCT07029828)
DESCRIPTION:PF-06651600\, phase 3.\nStudy: A Long-Term Study to Learn About
  The Study Medicine Called Ritlecitinib in Children With Severe Alopecia A
 reata.\nEstimated primary completion: 26 June 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07029828
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05895786-5753@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20300729
DTEND;VALUE=DATE:20300730
SUMMARY:PF-06823859: Phase 3 readout est. (NCT05895786)
DESCRIPTION:PF-06823859\, phase 3\, Dermatomyositis.\nStudy: A Study to Und
 erstand How the Study Medicine (PF-06823859) Works in People With Active I
 diopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (
 PM)]\nEstimated primary completion: 29 July 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pf-06823859#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05895786
URL:https://assetmemo.bio/drug/pf-06823859#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04743141-10363@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Rimegepant (Nurtec ODT): Phase 3 readout est. (NCT04743141)
DESCRIPTION:Rimegepant (Nurtec ODT)\, phase 3\, Migraine.\nStudy: Long-term
  Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment 
 of Migraine\nEstimated primary completion: 31 July 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04743141
URL:https://assetmemo.bio/drug/rimegepant-nurtec-odt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07470879-13@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20300908
DTEND;VALUE=DATE:20300909
SUMMARY:Velsipity (etrasimod): Phase 2 readout est. (NCT07470879)
DESCRIPTION:Velsipity (etrasimod)\, phase 2\, Ulcerative Colitis.\nStudy: A
  Study of How the Medicine Called "Etrasimod" Works in Children With the G
 ut Disease Called Ulcerative Colitis\nEstimated primary completion: 8 Sept
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etrasimod
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 70879
URL:https://assetmemo.bio/drug/etrasimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05623020-3143@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20301018
DTEND;VALUE=DATE:20301019
SUMMARY:Elranatamab: Phase 3 readout est. (NCT05623020)
DESCRIPTION:Elranatamab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Le
 arn About the Effects of the Combination of Elranatamab\, Daratumumab and 
 Lenalidomide Compared With Daratumumab\, Bortezomib\, Lenalidomide\, and D
 examethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not
  Candidates for Transplant\nEstimated primary completion: 18 October 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05623020
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363694-1455@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20301024
DTEND;VALUE=DATE:20301025
SUMMARY:tilrekimig: Phase 2/3 readout est. (NCT07363694)
DESCRIPTION:tilrekimig\, phase 2/3\, Chronic Obstructive Pulmonary Disease.
 \nStudy: A Study to Learn About the Study Medicine Called PF-07275315 in P
 eople With Moderate to Severe Chronic Obstructive Pulmonary Disease\nEstim
 ated primary completion: 24 October 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tilrekimig#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07363694
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392892-1989@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20310722
DTEND;VALUE=DATE:20310723
SUMMARY:PF-08634404: Phase 2/3 readout est. (NCT07392892)
DESCRIPTION:PF-08634404\, phase 2/3.\nStudy: Symbiotic-GI-16: A Study to Le
 arn About the Study Medicine Called PF-08634404 in Combination With Chemot
 herapy in Gastroesophageal Cancer\nEstimated primary completion: 22 July 2
 031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pf-08634404#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07392892
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06698796-5753@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20310729
DTEND;VALUE=DATE:20310730
SUMMARY:PF-06823859: Phase 3 readout est. (NCT06698796)
DESCRIPTION:PF-06823859\, phase 3\, Dermatomyositis.\nStudy: A Study to Und
 erstand How the Study Medicine Dazukibart Works in People With Idiopathic 
 Inflammatory Myopathies\nEstimated primary completion: 29 July 2031. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pf-06823859#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06698796
URL:https://assetmemo.bio/drug/pf-06823859#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06807281-1302@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20320222
DTEND;VALUE=DATE:20320223
SUMMARY:Cibinqo (abrocitinib): Phase 3 readout est. (NCT06807281)
DESCRIPTION:Cibinqo (abrocitinib)\, phase 3\, Atopic Dermatitis.\nStudy: A 
 Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Year
 s and Older With Moderate to Severe Eczema\nEstimated primary completion: 
 22 February 2032. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abr
 ocitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06807281
URL:https://assetmemo.bio/drug/abrocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890597-9131@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20320413
DTEND;VALUE=DATE:20320414
SUMMARY:Atirmociclib: Phase 3 readout est. (NCT07890597)
DESCRIPTION:Atirmociclib\, phase 3.\nStudy: A Study of a Medicine Called At
 irmociclib in Combination With Giredestrant in Adult Participants With ER-
 positive\, HER2-negative Early-stage Breast Cancer\nEstimated primary comp
 letion: 13 April 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/atirmociclib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07890597
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686394-2271@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20320802
DTEND;VALUE=DATE:20320803
SUMMARY:Tucatinib: Phase 1/2 readout est. (NCT06686394)
DESCRIPTION:Tucatinib\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: St
 udy of Patritumab Deruxtecan With Other Anticancer Agents in Participants 
 With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically 
 Removed (MK-1022-009)\nEstimated primary completion: 2 August 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06686394
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223697-20@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:afimkibart: Phase 2 readout est. (NCT07223697)
DESCRIPTION:afimkibart\, phase 2\, Atopic Dermatitis.\nStudy: A Long Term E
 xtension Study to Evaluate the Safety and Efficacy of Afimkibart (RO779012
 1) in Participants With Atopic Dermatitis\nEstimated primary completion: 1
  March 2033. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/afimkiba
 rt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7223697
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620392-20@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20330708
DTEND;VALUE=DATE:20330709
SUMMARY:afimkibart: Phase 2 readout est. (NCT07620392)
DESCRIPTION:afimkibart\, phase 2\, Rheumatoid Arthritis.\nStudy: An Extensi
 on Study to Assess Long-Term Safety and Efficacy of Afimkibart in Particip
 ants With Rheumatoid Arthritis\nEstimated primary completion: 8 July 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/afimkibart#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07620392
URL:https://assetmemo.bio/drug/afimkibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839884-1455@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20340421
DTEND;VALUE=DATE:20340422
SUMMARY:tilrekimig: Phase 3 readout est. (NCT07839884)
DESCRIPTION:tilrekimig\, phase 3\, Chronic Obstructive Pulmonary Disease.\n
 Study: A Continuation Study of Tilrekimig in Adults With Moderate-to-Sever
 e Long-Term Breathing Difficulty\, Known by the Medical Term of Chronic Ob
 structive Pulmonary Disease (COPD) to Learn About This Medicine When Used 
 for a Long Period of Time\nEstimated primary completion: 21 April 2034. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tilrekimig#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07839884
URL:https://assetmemo.bio/drug/tilrekimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
